SPORE in Prostate Cancer

描述（由申请人提供）： 本申请代表了前列腺癌卓越研究专业计划（SPORE）的创建，该计划源于新配置的Dana-Farber哈佛癌症中心（DF/HCC）的前列腺癌计划。DF/HCC前列腺癌孢子包括来自所有哈佛附属医院的研究人员;贝斯以色列女执事医院，布里格姆妇女医院，达纳法伯癌症研究所，马萨诸塞州总医院和哈佛公共卫生学院。通过这项申请支持五个主要项目，包括：1）PI 3/激酶的遗传和血清学标记 前列腺癌中的Akt通路; 2）过氧化物酶体增殖物激活物受体γ作为前列腺癌治疗的靶点; 3）前列腺癌的遗传分类; 4）前列腺癌结果的表达分析预测;以及5）激素难治性前列腺癌中的雄激素受体。这些项目将通过建立四个核心加以整合。这些是：1）管理，评估和规划; 2）生物统计学; 3）组织和病理学;和4）基因组学。此SPORE应用程序概述了一个开发项目计划，其中包括一个新项目的选择计划，以及七个可以 supported.我们还包括一个职业发展奖励计划，概述了一个机制，用于识别和支持有才华的年轻研究人员在前列腺癌。DFHCC SPORE的总体目标是将生物和技术进步转化为对前列腺癌患者有临床意义的进步。

DESCRIPTION (provided by applicant): This application represents the creation of a Specialized Program of Research Excellence (SPORE) in Prostate Cancer originating from the Prostate Cancer Program of the newly configured Dana-Farber Harvard Cancer Center (DF/HCC). The DF/HCC Prostate Cancer SPORE includes investigators from all the Harvard affiliated hospitals; The Beth Israel Deaconess Hospital, the Brigham & Women's Hospital, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, and the Harvard School of Public Health. Five major projects are supported through this application including: 1) Genetic and serological markers of the PI3/Kinase Akt pathway in prostate cancer; 2) the peroxisome proliferator activator receptor gamma as a target for prostate cancer therapy; 3) the genetic classification of prostate cancer; 4) Expression analysis prediction of prostate cancer outcome; and 5) the androgen receptor in hormone refractory prostate cancer. These projects will be integrated by the creation of four cores. These are: 1) Administration, evaluation, and planning; 2) Biostatistics; 3) Tissue and Pathology; and 4) Genomics. This SPORE application outlines a Developmental Projects Program that includes a plan for selection of new projects as well as seven pilot projects that could be supported. We also include a Career Development Award Program that outlines a mechanism for the identification and support of talented young investigators in prostate cancer. The overall goal of the DFHCC SPORE is the translation of biological and technological advances into clinically meaningful advances for men with prostate cancer.